Breaking News
Get 60% Off 0
Black Friday Sale! Save huge on InvestingPro
Get up to 60% off
Close

Axa Spdb Strategy Emerg Inds Bal Fd A (519120)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
3.373 +0.050    +1.53%
27/11 - Closed. Currency in CNY
Type:  Fund
Market:  China
Asset Class:  Equity
  • Morningstar Rating:
  • Total Assets: 382.55M
AXA SPDB Strategy Emerging Industries Balance Fund 3.373 +0.050 +1.53%

519120 Holdings

 
Comprehensive information about top holdings and Key Holding Information for the AXA SPDB Strategy Emerging Industries Balance Fund (519120) fund. Our AXA SPDB Strategy Emerging Industries Balance Fund portfolio information includes stock holdings, annual turnover, top 10 holdings, sector and asset allocation.

Asset Allocation

Create Alert
Add to Watchlist
Add to/Remove from a Portfolio  
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Name  Net %  Long %  Short %
Cash 10.510 10.510 0.000
Shares 82.190 82.190 0.000
Bonds 3.580 3.580 0.000
Other 3.730 3.730 0.000

 Style Box

Value & Growth Measures

Ratios Value Category Average
P/E Ratio 13.271 17.577
Price to Book 1.617 2.212
Price to Sales 1.442 1.726
Price to Cash Flow 6.165 9.656
Dividend Yield 2.956 2.492
5 Years Earnings Growth 24.089 16.876

Sector Allocation

Name  Net % Category Average
Technology 38.530 24.851
Industrials 19.780 24.258
Utilities 14.320 6.273
Consumer Cyclical 11.950 11.033
Basic Materials 8.800 11.743
Healthcare 6.330 9.773
Financial Services 0.300 7.361

Region Allocation

  • Asia
  • Emerging Markets

Top Holdings

Number of long holdings: 48

Number of short holdings: 1

Name ISIN Weight % Last Change %
  Sailun Jinyu CNE1000015F7 8.92 14.56 +0.90%
  Luxshare Precision A CNE100000TP3 8.44 38.20 -2.38%
  Suzhou Maxwell CNE100003FS0 5.35 122.98 -0.89%
  Bestechnic Shanghai Co CNE100005XM1 5.32 274.91 +5.59%
  Grandblue Environment CNE000001675 4.90 21.58 -0.09%
  Chongqing Sanfeng Environment Group CNE100003ZV2 4.76 8.49 +0.24%
  Xingrong Invest A CNE000000HN4 4.75 7.09 -1.12%
  Suzhou Xianglou New Material CNE100005DS0 4.54 53.96 +2.74%
  Shenzhen Transsion CNE100003P74 4.29 85.05 +0.83%
  Humanwell Healthcare CNE000000QW6 4.22 22.53 -0.44%

Top Equity Funds by AXA SPDB Investment Managers Co.,Ltd

  Name Rating Total Assets YTD% 3Y% 10Y%
  AXA SPDB CSI 300 Index Strengthen F 734.08M 13.02 -6.85 8.84
  AXA SPDB Consumption Upgrade Allo A 708.57M -2.23 -6.50 7.71
  AXA SPDB Consumption Upgrade Allo C 708.57M -2.34 -6.67 -
  AXA SPDB Growth flexible allocate 566.53M -1.35 -13.71 -
  AXA SPDB Dividend Selected Stock 562.51M -16.53 -14.01 8.24
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

519120 Comments

Write your thoughts about Axa Spdb Strategy Emerg Inds Bal Fd A
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email